Bluestar

Chinabluestar.com.cn

China National Bluestar (Group) Co., Ltd. (蓝星集团; Bluestar) is a Chinese state-owned chemical group headquartered in Beijing. It is part of China National Chemical Corporation (ChemChina), which is under Sinochem Holdings. Bluestar operates globally through manufacturing, R&D, and sales entities.

The group’s portfolio spans silicones and other silicon-based materials, fluorine-based and specialty chemicals, basic chemicals, and chemical engineering equipment. It also provides materials and solutions for environmental protection and water treatment, such as resins and membrane technologies. Its products serve end markets including automotive, electronics, construction, energy, agriculture, and consumer goods.

Through international investments and acquisitions, Bluestar has built a significant overseas footprint. Notable holdings have included Elkem (advanced materials, including silicon, silicones, and carbon products) and Adisseo (animal nutrition). The group focuses on integrating upstream raw materials with downstream specialty products across the value chain.

Also known as China National BlueStar.

Latest news on Bluestar

30 April 2026
Elkem completes sale of Silicones division to Bluestar and redeems Bluestar shares

Registered share capital is NOK 1,505,514,210 (301,102,842 shares, NOK 5 par). Board and Nomination Committee changes took effect; seller no longer represented.

8 April 2026
Elkem's Helge Aasen to step down as CEO, nominated as board chairman

Nomination committee’s proposals take effect after completion of the majority Silicones sale to Bluestar; the current CEO will stay on until a successor is in place. AGM 30 Apr 2026.

11 March 2026
Elkem Restructures and Cuts Costs to Boost Competitiveness

Elkem introduces a new structure, reduces workforce by 300, and cuts costs by NOK 1.9 billion to enhance profitability amid market challenges.

13 February 2026
Elkem to Sell Majority of Silicones Division to Bluestar

Elkem to transfer Silicones division to Bluestar, settling through share redemption. Transaction awaits shareholder and regulatory approvals, expected to close by May 2026.